Skip to main content
< Back to news

Barcelona becomes a focus of interest for international biotechnology investors

Yesterday and today, 26 and 27 September, the Barcelona Science Park (PCB) is hosting the 1st edition of the Asebio Investor Day, an event organised by Asebio and the Spanish Biotech Platform –as part of the European Biotech Week– in collaboration with the PCB and Biocat, and with support from ICEX-Invest in Spain.


The aim of the Asebio Investor Day is to consolidate the Spanish biotechnological market as the hub of international biotechnology, and as a focus of interest for national and international investment. The event now also helps companies seek funding and move into foreign markets.

The initiative is based around two events: a workshop on capital raising mechanisms, partnerships and other business development strategies, which was given yesterday by Johnson & Johnson Innovation (JLABS), and a funding forum which today saw the participation of leading investors and pharmaceutical companies from around the world.

During the course of the workshop, Lilian Alcaraz, New Ventures and Transactions Lead for Neuroscience at Johnson & Johnson Innovation, explained the keys for success when preparing an executive summary aimed at investors. Rick Davis, Senior Director of New Ventures and Transactions for Oncology, revealed the essential business development skills for successfully evaluating and administering strategic partnerships and other potential growth opportunities.

In the funding forum, which was held today, 30 national projects were presented to 50 investors from Spain, Great Britain, Switzerland and France. It also included a session of one-to-one meetings. 

PCB companies, leaders in raising international capital

In 2016, Spanish biotechnology companies continued raising international capital in unprecedented amounts in Spain, according to data published in the latest Asebio Annual Report. Seventy-seven biotech operations were carried out in the country last year, with an investment of 127 million euros coming from increased private capital, public stock listings, share issues, corporate operations, supplementary funding and venture capital activity. The increased international investment has been led by Aelix Therapeutics, Iproteos, SOM Biotech and STAT-Dx, which are based in the Barcelona Science Park.


► More information on the Asebio website [+]